Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price hoisted by research analysts at Oppenheimer from $625.00 to $675.00 in a report issued on Wednesday, The Fly reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target points to a potential upside of 8.44% from the company’s current price.
Several other equities research analysts also recently commented on REGN. Benchmark started coverage on Regeneron Pharmaceuticals in a report on Sunday, April 19th. They issued a “hold” rating for the company. ValuEngine raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, March 9th. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $466.00 to $525.00 and gave the company a “market perform” rating in a report on Wednesday, May 6th. Piper Sandler increased their price objective on Regeneron Pharmaceuticals from $550.00 to $600.00 in a report on Wednesday, May 6th. Finally, Wells Fargo & Co raised Regeneron Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $559.00 to $734.00 in a report on Tuesday, May 26th. Fifteen analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Buy” and a consensus price target of $550.64.
Shares of REGN opened at $622.45 on Wednesday. The stock has a market capitalization of $67.02 billion, a P/E ratio of 31.28, a P/E/G ratio of 1.92 and a beta of 0.58. Regeneron Pharmaceuticals has a twelve month low of $271.37 and a twelve month high of $646.33. The company has a 50 day moving average of $595.43 and a 200-day moving average of $478.59. The company has a quick ratio of 3.49, a current ratio of 4.21 and a debt-to-equity ratio of 0.06.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share for the quarter, topping the consensus estimate of $6.13 by $0.47. The company had revenue of $1.83 billion during the quarter, compared to analysts’ expectations of $1.81 billion. Regeneron Pharmaceuticals had a net margin of 28.56% and a return on equity of 24.94%. The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period last year, the business earned $4.45 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 23.48 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 3,613 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $607.62, for a total value of $2,195,331.06. Following the transaction, the director now owns 4,256 shares in the company, valued at $2,586,030.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Robert E. Landry sold 696 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $497.52, for a total value of $346,273.92. Following the completion of the transaction, the chief financial officer now owns 27,373 shares in the company, valued at approximately $13,618,614.96. The disclosure for this sale can be found here. Insiders sold 211,123 shares of company stock worth $121,018,015 in the last 90 days. 11.84% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in REGN. OmniStar Financial Group Inc. bought a new position in Regeneron Pharmaceuticals in the first quarter valued at about $28,000. CX Institutional grew its position in Regeneron Pharmaceuticals by 144.0% in the first quarter. CX Institutional now owns 61 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 36 shares during the last quarter. Parkside Financial Bank & Trust grew its position in Regeneron Pharmaceuticals by 44.2% in the first quarter. Parkside Financial Bank & Trust now owns 62 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 19 shares during the last quarter. Globeflex Capital L P bought a new position in Regeneron Pharmaceuticals in the first quarter valued at about $31,000. Finally, Americana Partners LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $39,000. Hedge funds and other institutional investors own 68.04% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: How does quantitative easing work?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.